Free Trial
→ Buffett, Gates and Bezos Dumping Stocks (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:TVGN

Tevogen Bio 8/19/2025 Earnings Report

Tevogen Bio logo
$0.87 -0.01 (-1.55%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.87 0.00 (-0.34%)
As of 09/12/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Tevogen Bio EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Tevogen Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tevogen Bio Announcement Details

Quarter
Date
8/19/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Tevogen Bio's next earnings date is estimated for Monday, November 10, 2025, based on past reporting schedules.

Conference Call Resources

Tevogen Bio Earnings Headlines

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10 at 11:59 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/10/3148013/0/en/tevogen-cio-and-head-of-tevogen-ai-mittul-mehta-to-join-startup-forum-panel-at-databricks-data-ai-world-tour-in-boston.html
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/09/3147304/0/en/tevogen-estimates-5-year-top-line-revenue-of-6-5-billion-for-product-focused-on-liver-cancer-prevention-with-high-risk-chronic-hepatitis-b-infection.html
2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
September 13 at 2:00 AM  |  Crypto Swap Profits (Ad)
Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform
September 9, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-09/66381902-tevogen-bio-inc-tevogen-values-tvgn-489-at-dollar-9-dollar-11-billion-rnpv-its-first-clinical-product-from-the-proprietary-exactcell-allogeneic-t-cell-platform-399.htm
Tevogen values TVGN-480 at $9B-$11B rNPV
September 9, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/tevogen-values-tvgn-480-at-9b-11b-rnpv/ar-AA1M7YYI
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/08/3146171/0/en/tevogen-values-tvgn-489-at-9-11-billion-rnpv-its-first-clinical-product-from-the-proprietary-exactcell-allogeneic-t-cell-platform.html
See More Tevogen Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email.

About Tevogen Bio

Tevogen Bio (NASDAQ:TVGN) plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections. Its research and development efforts seek to harness both non-engineered and engineered NK cells, including chimeric antigen receptor (CAR) NK constructs, to address a broad range of diseases. The company’s technology platform is protected by patents covering manufacturing processes and product compositions.

Founded in 2013 by a team of immunotherapy experts, Tevogen Bio maintains research facilities in the United States, Israel and Denmark. Under the leadership of co-founder and Chief Executive Officer Khurshid Guru, the company has progressed from early-stage discovery to clinical development. It is actively expanding its manufacturing capabilities to support late-stage trials and future commercialization efforts.

Tevogen Bio collaborates with academic institutions and drug development partners to accelerate its pipeline. The company engages with regulatory authorities in North America and Europe as it advances clinical programs and prepares for potential market entry. By focusing on the innate immune system and personalized therapeutic approaches, Tevogen Bio aims to address unmet medical needs in oncology and viral disease treatment.

View Tevogen Bio Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles